文献速递白血病淋巴瘤

布鲁顿酪氨酸激酶抑制增加慢性淋巴细胞白血病对BCL-2的依赖并增强对维奈克拉的敏感性

Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2017-01-23

研究采用动态BH3谱分析,检测伊布替尼和阿可替尼对慢性淋巴细胞白血病(CLL)患者样本线粒体凋亡通路的影响。发现BTK抑制增加线粒体BCL-2依赖并上调促凋亡蛋白BIM,且无论体外还是体内预处理均增强维奈克拉的杀伤作用。数据提示BTK抑制增加BCL-2依赖,支持BTK与BCL-2联合抑制的临床试验开展。

要点

  • BTK抑制增加CLL细胞线粒体BCL-2依赖,不显著改变整体线粒体致敏状态。
  • BCL-2依赖增强伴随促凋亡蛋白BIM增加。
  • 维奈克拉增强整体线粒体致敏但不增加BCL-2依赖;BTK抑制预处理增强维奈克拉杀伤。

核心结论

  • BTK抑制增加线粒体BCL-2依赖,支持BTK与BCL-2抑制联合的临床试验继续开展。

研究设计与样本

  • 使用动态BH3谱分析,检测伊布替尼和阿可替尼处理的CLL患者样本(体外用药及临床试验中患者原代样本)线粒体凋亡通路功能变化。

主要发现

  • BTK抑制增强线粒体BCL-2依赖,未显著改变整体线粒体致敏状态。
  • BCL-2依赖增强伴随促凋亡蛋白BIM增加。
  • 维奈克拉增强整体线粒体致敏,但不增加BCL-2依赖。
  • 无论体外或患者体内,BTK抑制预处理均增强维奈克拉对CLL细胞的杀伤。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial apoptosis in vitro, and as such the mechanisms underlying its ability to kill CLL cells are not well understood. Acalabrutinib, a more specific BTK inhibitor now in development, also appears to be highly effective in CLL, but the connection of its mechanism with CLL cell death is also unclear. Using dynamic BH3 profiling, we analyzed alterations in the function of the mitochondrial apoptotic pathway induced by ibrutinib and acalabrutinib. We studied CLL patient samples treated ex vivo with both drugs, as well as primary samples from CLL patients on clinical trials of both drugs. We found that BTK inhibition enhances mitochondrial BCL-2 dependence without significantly altering overall mitochondrial priming. Enhancement of BCL-2 dependence was accompanied by an increase in the pro-apoptotic protein BIM. In contrast, treatment with the selective BCL-2 inhibitor venetoclax enhanced overall mitochondrial priming without increasing BCL-2 dependence. Pre-treatment of CLL cells with either BTK inhibitor, whether ex vivo or in vivo in patients, enhanced killing by venetoclax. Our data suggest that BTK inhibition enhances mitochondrial BCL-2 dependence, supporting the ongoing development of clinical trials combining BTK and BCL-2 inhibition.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Deng J, Isik E, Fernandes SM, et al. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017. PMID: 28111464. doi:10.1038/leu.2017.32

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。